Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EMBC NYSE:ENOV NASDAQ:NVCR NYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMBCEmbecta$9.58-7.6%$10.62$9.20▼$21.48$606.05M1.08500,804 shs589,242 shsENOVEnovis$30.90-3.3%$32.87$28.83▼$49.83$1.83B1.7908,943 shs1.56 million shsNVCRNovoCure$16.79-3.6%$17.66$14.17▼$34.13$1.94B0.721.12 million shs740,350 shsWRBYWarby Parker$22.92-0.4%$20.80$12.46▼$28.68$2.40B2.091.99 million shs1.43 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMBCEmbecta-7.62%-8.15%+0.21%-15.52%-25.39%ENOVEnovis-3.15%-11.05%-3.01%-0.68%-30.93%NVCRNovoCure-3.62%-4.11%-4.33%+6.06%-6.67%WRBYWarby Parker-0.44%+2.21%+3.97%+61.03%+40.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMBCEmbecta4.7532 of 5 stars3.23.03.30.02.93.33.8ENOVEnovis2.4568 of 5 stars3.41.00.00.01.51.71.9NVCRNovoCure3.5167 of 5 stars3.41.00.04.52.01.70.0WRBYWarby Parker2.4523 of 5 stars2.35.00.00.01.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMBCEmbecta 2.33Hold$19.33101.81% UpsideENOVEnovis 2.80Moderate Buy$55.6079.94% UpsideNVCRNovoCure 2.71Moderate Buy$32.4393.14% UpsideWRBYWarby Parker 2.53Moderate Buy$22.88-0.17% DownsideCurrent Analyst Ratings BreakdownLatest EMBC, WRBY, NVCR, and ENOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025WRBYWarby ParkerJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform7/10/2025WRBYWarby ParkerCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform7/8/2025ENOVEnovisEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$48.00 ➝ $46.007/8/2025NVCRNovoCureLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/27/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.005/29/2025WRBYWarby ParkerPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$20.00 ➝ $25.005/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/22/2025WRBYWarby ParkerRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$18.00 ➝ $21.005/21/2025WRBYWarby ParkerCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMBCEmbecta$1.12B0.50$3.08 per share3.11($12.80) per share-0.75ENOVEnovis$2.11B0.84$18.61 per share1.66$45.10 per share0.69NVCRNovoCure$605.22M3.09N/AN/A$3.33 per share5.04WRBYWarby Parker$771.32M3.10$0.34 per share67.78$3.35 per share6.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMBCEmbecta$78.30M$0.9010.643.120.674.89%-19.67%12.27%8/8/2025 (Estimated)ENOVEnovis-$825.49M-$13.95N/A9.69N/A-37.65%5.99%3.44%8/6/2025 (Estimated)NVCRNovoCure-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)WRBYWarby Parker-$20.39M-$0.12N/A229.15N/A-1.79%-2.48%-1.29%8/6/2025 (Estimated)Latest EMBC, WRBY, NVCR, and ENOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q3 2025EMBCEmbecta$0.7720N/AN/AN/A$278.15 millionN/A8/6/2025Q2 2025ENOVEnovis$0.74N/AN/AN/A$555.80 millionN/A7/24/2025Q2 2025NVCRNovoCure-$0.40N/AN/AN/A$153.87 millionN/A5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMBCEmbecta$0.606.26%N/A66.67%N/AENOVEnovisN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/AWRBYWarby ParkerN/AN/AN/AN/AN/ALatest EMBC, WRBY, NVCR, and ENOV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMBCEmbectaN/A2.481.83ENOVEnovis0.522.551.32NVCRNovoCure0.271.471.41WRBYWarby ParkerN/A2.702.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMBCEmbecta93.83%ENOVEnovis98.45%NVCRNovoCure84.61%WRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipEMBCEmbecta0.42%ENOVEnovis2.70%NVCRNovoCure5.52%WRBYWarby Parker18.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMBCEmbecta2,10058.44 million58.20 millionOptionableENOVEnovis7,36757.12 million55.58 millionOptionableNVCRNovoCure1,488111.49 million105.33 millionOptionableWRBYWarby Parker3,780104.50 million85.44 millionOptionableEMBC, WRBY, NVCR, and ENOV HeadlinesRecent News About These CompaniesWarby Parker Inc. (NYSE:WRBY) Shares Bought by Bank of New York Mellon Corp4 hours ago | marketbeat.comWarby Parker (NYSE:WRBY) Stock Price Up 5.9% - Here's WhyJuly 14 at 4:02 PM | marketbeat.comWarby Parker Inc. (NYSE:WRBY) Shares Sold by TimesSquare Capital Management LLCJuly 14 at 8:51 AM | marketbeat.comContrasting Warby Parker (WRBY) & The CompetitionJuly 14 at 2:55 AM | americanbankingnews.comWarby Parker (NYSE:WRBY) Cut to Market Perform at Citizens JmpJuly 13 at 3:31 AM | americanbankingnews.comWarby Parker's (WRBY) Market Perform Rating Reiterated at JMP SecuritiesJuly 13 at 3:31 AM | americanbankingnews.comJMP Securities Downgrades Warby Parker (WRBY)July 11, 2025 | msn.comWarby Parker (NYSE:WRBY) Receives "Market Perform" Rating from JMP SecuritiesJuly 10, 2025 | marketbeat.comWarby Parker (NYSE:WRBY) Stock Rating Lowered by Citizens JmpJuly 10, 2025 | marketbeat.comWarby Parker Inc. Stock Grades | WRBY - Barron'sJuly 10, 2025 | barrons.comWarby Parker Inc. (NYSE:WRBY) Receives $22.88 Average PT from AnalystsJuly 9, 2025 | americanbankingnews.comWinners And Losers Of Q1: Warby Parker (NYSE:WRBY) Vs The Rest Of The Beauty and Cosmetics Retailer StocksJuly 8, 2025 | msn.comWarby Parker Inc. (NYSE:WRBY) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 6, 2025 | americanbankingnews.comWarby Parker Inc. (NYSE:WRBY) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 6, 2025 | marketbeat.com11,751 Shares in Warby Parker Inc. (NYSE:WRBY) Acquired by Diversified Trust CoJuly 2, 2025 | marketbeat.comWhat Makes Warby Parker (WRBY) an Attractive Investment?June 30, 2025 | finance.yahoo.comBessemer Group Inc. Has $1.17 Million Stock Position in Warby Parker Inc. (NYSE:WRBY)June 30, 2025 | marketbeat.comWRBY - Warby Parker Inc Ordinary Shares - Class A Chart - MorningstarJune 28, 2025 | morningstar.comMThe 5 Most Interesting Analyst Questions From Warby Parker’s Q1 Earnings CallJune 27, 2025 | msn.comWarby Parker (NYSE:WRBY) Stock Price Down 3.7% - Here's What HappenedJune 26, 2025 | marketbeat.comSG Americas Securities LLC Buys Shares of 33,023 Warby Parker Inc. (NYSE:WRBY)June 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEMBC, WRBY, NVCR, and ENOV Company DescriptionsEmbecta NASDAQ:EMBC$9.58 -0.79 (-7.62%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$9.56 -0.03 (-0.26%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Enovis NYSE:ENOV$30.90 -1.06 (-3.32%) Closing price 07/15/2025 03:59 PM EasternExtended Trading$30.90 0.00 (-0.02%) As of 07/15/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.NovoCure NASDAQ:NVCR$16.79 -0.63 (-3.62%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$16.98 +0.19 (+1.10%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Warby Parker NYSE:WRBY$22.92 -0.10 (-0.41%) Closing price 07/15/2025 03:59 PM EasternExtended Trading$22.70 -0.22 (-0.94%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
